A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis
Phase of Trial: Phase III
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 24 Jul 2017 Planned End Date changed from 1 May 2019 to 15 May 2019.
- 24 Jul 2017 Planned primary completion date changed from 1 May 2019 to 15 May 2019.
- 15 Jul 2016 Planned number of patients changed from 605 to 940.